Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA 02451, USA.
Biochem Pharmacol. 2012 Sep 1;84(5):654-60. doi: 10.1016/j.bcp.2012.06.017. Epub 2012 Jun 26.
The NAD-dependent DNA ligase is an excellent target for the discovery of antibacterial agents with a novel mode of action. In this work the DNA ligase from Streptococcus pneumoniae was investigated for its steady-state kinetic parameters and inhibition by compounds with an adenosine substructure. Inhibition by substrate DNA that was observed in the enzyme turnover experiments was verified by direct binding measurements using isothermal titration calorimetry (ITC). The substrate-inhibited enzyme form was identified as deadenylated DNA ligase. The binding potencies of 2-(butylsulfanyl) adenosine and 2-(cyclopentyloxy) adenosine were not significantly affected by the presence of the enzyme-bound DNA substrate. Finally, a mutant protein was prepared that was known to confer resistance to the adenosine compounds' antibacterial activity. The mutant protein was shown to have little catalytic impairment yet it was less susceptible to adenosine compound inhibition.
NAD 依赖的 DNA 连接酶是发现具有新型作用模式的抗菌剂的极佳靶点。在这项工作中,研究了肺炎链球菌的 DNA 连接酶的稳态动力学参数及其被具有腺苷结构的化合物的抑制作用。通过使用等温滴定量热法(ITC)进行直接结合测量,验证了在酶周转实验中观察到的由 DNA 底物引起的抑制作用。通过直接结合测量,验证了在酶周转实验中观察到的由 DNA 底物引起的抑制作用。被抑制的酶形式被鉴定为去腺苷化 DNA 连接酶。结合物 2-(丁基硫基)腺苷和 2-(环戊氧基)腺苷的结合效力不受酶结合 DNA 底物存在的显著影响。最后,制备了一种已知对抗腺苷化合物抗菌活性具有抗性的突变蛋白。该突变蛋白的催化损伤较小,但对腺苷化合物的抑制作用的敏感性较低。